DETECTion of PeriOperative Atrial Fibrillation After Noncardiac Surgery

Recruiting now

Conditions studied: Atrial Fibrillation, Atrial Flutter

In brief

This is a multicentre prospective cohort study where patients will receive up to 14 days of continuous ECG monitoring by wearing a portable monitoring device, starting within 72 hours after noncardiac surgery.

Key facts

Study ID

NCT06519747

Run by

Population Health Research Institute

People needed

750

Starts

2024-10-15

Expected to finish

2026-12-31

Last updated by the study team

2024-11-07

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Had undergone noncardiac surgery within the past 72 hours and requiring, or expected to require, at least one of the following:
• an overnight hospital admission after surgery
• day surgery that would result in a large enough physiological insult to be able to cause POAF. Procedures excluded include those that are conducted using local anesthesia alone, are less than 30 minutes in duration, and/or are judged to be of low physiologic insult by the local investigator.
• Have one of the following high-risk criteria;
• age 55-64 years, and having either established cardiovascular disease, recent major vascular surgery, a CHA2DS2-VASc score ≥3, or an elevated postoperative troponin level;
• age 65-74 years, and having either established cardiovascular disease, recent major vascular surgery, a CHA2DS2-VASc score ≥2, or an elevated postoperative troponin level; or
• age ≥75 years;
• Provide written informed consent to participate.

You may not qualify if…

• History of documented chronic (i.e., non-transient) AF before noncardiac surgery;
• Need for long-term systemic anticoagulation;
• Ongoing need for long-term dual antiplatelet treatment;
• Contraindication to oral anticoagulation;
• Severe renal insufficiency;
• Severe liver cirrhosis;
• Acute stroke in the past 14 days;
• Underwent cardiac surgery in the past 35 days;
• History of nontraumatic intracranial, intraocular, or spinal bleeding;
• Hemorrhagic disorder or bleeding diathesis;
• Known life expectancy <1 year due to concomitant disease;
• Women who are pregnant, breastfeeding, or of childbearing potential not taking effective contraception;
• Expected to be non-compliant with follow-up and/or device use;
• Known contact allergy to monitoring device and/or its peripheral components;
• Previously enrolled in DETECT-POAF.

Where it is running

• Hamilton General Hospital — Hamilton, Ontario, Canada (enrolling)
• Juravinski Hospital — Hamilton, Ontario, Canada (enrolling)
• St. Joseph's Healthcare Hamilton — Hamilton, Ontario, Canada
• London Health Sciences Centre - University Hospital — London, Ontario, Canada
• Niagara Health System - St. Catharine's Site — St. Catharines, Ontario, Canada
• Hôpital Fleurimont du Centre hospitalier universitaire de Sherbrooke — Sherbrooke, Quebec, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.